title: The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever.
abstract: We aimed to evaluate some of the vascular biomarkers in newly diagnosed, colchicine naive familial Mediterranean fever (FMF) patients. Our primary aim was to investigate the effect of regular colchicine treatment on these variables. Twenty-four (12 males [M] and 12 females [F], 33.3 ± 13.4 years) newly diagnosed FMF patients were included in the study. These patients were started on colchicine treatment following the initial assessment and were studied again no earlier than 2 months. Five patients were lost to follow-up, and assessment of the on-treatment patients was performed on the remaining 19 patients (8 M and 11 F, 33.6 ± 11.8 years). There were 19 healthy subjects (11 M and 8 F, 32.2 ± 7.2 years) who served as a control group. Cellular adhesion molecules (CAMs; soluble intercellular adhesion molecule-1 [sICAM-1] and soluble CD146 [sCD146]), plasminogen activator inhibitor-1 (PAI-1), fetuin-A and hs-CRP were studied. Examinations were performed on attack-free periods. The levels of hs-CRP, fetuin-A, sICAM-1, and PAI-1 were significantly higher in newly diagnosed patients compared to those of controls (P < 0.05). All studied parameters were significantly downregulated after regular colchicine therapy (P < 0.05). Comparison of on-treatment data with controls showed that the levels of the vascular biomarkers, except sCD146, were similar between the groups (P > 0.05). On-treatment sCD146 was found significantly lower than the controls (P < 0.05). In regression analysis, none of the independent variables in the model significantly predicted the vascular biomarkers (P > 0.05). Administration of therapeutic doses of colchicine markedly reduces vascular injury parameters and normalizes the values in FMF.
authors.affiliation: Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey. ismailsari35@gmail.com
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.forename: Arif
authors.initials: A
authors.lastname: Yuksel
authors.forename: Didem
authors.initials: D
authors.lastname: Kozaci
authors.forename: Sema
authors.initials: S
authors.lastname: Selcuk
authors.forename: Goksel
authors.initials: G
authors.lastname: Gokce
authors.forename: Yasar
authors.initials: Y
authors.lastname: Yildiz
authors.forename: Hakan
authors.initials: H
authors.lastname: Demirel
authors.forename: Gulten
authors.initials: G
authors.lastname: Sop
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: Necati
authors.initials: N
authors.lastname: Gunay
authors.forename: Nurullah
authors.initials: N
authors.lastname: Akkoc
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D051929:CD146 Antigen / Q000097:blood; D003078:Colchicine / Q000494:pharmacology / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D057772:Vascular System Injuries / Q000188:drug therapy; D060749:alpha-2-HS-Glycoprotein / Q000032:analysis
chemical_list: C556354:AHSG protein, human; D015415:Biomarkers; D051929:CD146 Antigen; C497902:MCAM protein, human; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D060749:alpha-2-HS-Glycoprotein; D018799:Intercellular Adhesion Molecule-1; D002097:C-Reactive Protein; D003078:Colchicine